Swiss agency approves trial for Ebola vaccine
The Swiss agency that regulates new drugs said yesterday it has approved an application for a clinical trial with an experimental Ebola
vaccine at the Lausanne University Hospital.
Swissmedic said the trial will be conducted among 120 volunteer participants with support from the UN World Health Organization (WHO). The experimental vaccine is to be initially administered on healthy volunteers who will be sent as medical staff to fight the Ebola epidemic in West Africa.
In a statement, the Bern-based Swiss government agency said the trial continues a series that began in the United States, Britain and Mali, using a vaccine based on a genetically modified chimpanzee adenovirus.
There are no proven drugs or vaccines for Ebola, mainly because the disease is so rare it?s been hard to attract research funding. But with governments and businesses now rapidly shifting millions of dollars to fight the Ebola epidemic centred in West Africa, WHO says two leading candidates for a vaccine have emerged.
One of them, now approved by Swissmedic for a trial, is a vaccine co-developed by the US National Institutes of Health and GlaxoSmithKline (GSK), which was funded by the company, its charitable trust and funds from the US and UK governments. GSK has said it might be able to make about one million doses of its vaccine per month by the end of 2015.